Cited by 272Schizophrenia research and treatmentAmino Acid Enzymes and MetabolismTryptophan and brain disorders

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients

Hashimoto, Kenji, Engberg, Göran, Shimizu, Eiji, Nordin, Conny, Lindström, Leif H., Iyo, Masaomi·2005·Progress in Neuro-Psychopharmacology and Biological Psychiatry

DOI 10.1016/j.pnpbp.2005.04.023

Open this paper in CoChat — free account

Abstract

Several lines of evidence suggest that D-serine, an endogenous agonist of the glycine site on the NMDA receptors, might play a role in the pathophysiology of schizophrenia. The purpose of this study was to determine whether levels of D- and L-serine or D-serine ratio (D-serine/total serine) in cerebrospinal fluid (CSF) were altered in first episode and drug-naive schizophrenic patients. The CSF levels of D- and L-serine in 25 male first episode and drug-naive schizophrenic patients and 17 age-matched male healthy subjects were measured using a column-switching high performance liquid chromatography system. The percentage of D-serine in the total serine of patients was significantly (z = -2.01, p = 0.044) lower than that of controls. This study suggests that synthetic or metabolic pathways of D-serine may be abnormal in the brain of drug-naive schizophrenic patients, supporting the NMDA receptor dysfunction hypothesis of schizophrenia.

Integrity signals

Registry

Crossref · 10.1016/j.pnpbp.2005.04.023

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Diagnostic and Statistical Manual of Mental Disorders
&NA; (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802020-00022 · Cited by 12,603
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
GOFF, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 926
Decreased Serum Levels of D-Serine in Patients With Schizophrenia
Hashimoto, K., Fukushima, T., Shimizu, E., Komatsu, N., Watanabe, H., 篠田, 直., Nakazato, M., Kumakiri, C., Okada, S.-I., Hasegawa, H., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.572 · Cited by 489
Self-citation
Schizophrenia and Glutamatergic Transmission
Tamminga, C. A. (1998) · Critical Reviews in Neurobiology · doi:10.1615/critrevneurobiol.v12.i1-2.20 · Cited by 382
Free d-aspartate and d-serine in the mammalian brain and periphery
Hashimoto, A., & Oka, T. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00019-1 · Cited by 332
Novel Neurotransmitters and Their Neuropsychiatric Relevance
Snyder, S. H., & Ferris, C. D. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.11.1738 · Cited by 263
Dysfunction of Glia-Neuron Communication in Pathophysiology of Schizophrenia
Hashimoto, K., Shimizu, E., & Iyo, M. (2005) · Current Psychiatry Reviews · doi:10.2174/1573400054065569 · Cited by 75
Self-citation

Show all 13 references

Sorted by citations

Astrocyte Control of Synaptic Transmission and Neurovascular Coupling
Haydon, P. G., & Carmignoto, G. (2006) · Physiological Reviews · doi:10.1152/physrev.00049.2005 · Cited by 1,371
Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
Increased Levels of Glutamate in Brains from Patients with Mood Disorders
Hashimoto, K., Sawa, A., & Iyo, M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.017 · Cited by 631
Self-citation
Glutamate and Schizophrenia: Phencyclidine, N‐Methyl‐d‐Aspartate Receptors, and Dopamine–Glutamate Interactions
Javitt, D. C. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 568
N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?
Kantrowitz, J. T., & Javitt, D. C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.04.006 · Cited by 414
Brain–gut–microbiota axis in depression: A historical overview and future directions
Chang, L., Wei, Y., & Hashimoto, K. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.02.004 · Cited by 407
Self-citation
Glutamate hypothesis in schizophrenia
Uno, Y., & Coyle, J. T. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12823 · Cited by 389
Neurophysiological biomarkers for drug development in schizophrenia
Javitt, D. C., Spencer, K., Thaker, G. K., Winterer, G., & Hajós, M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2463 · Cited by 340
A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia
Bendikov, I., Nadri, C., Amar, S., Panizzutti, R., DEMIRANDA, J., Wolosker, H., & Agam, G. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.10.010 · Cited by 323
d ‐Amino acids in the brain: d ‐serine in neurotransmission and neurodegeneration
Wolosker, H., Dumin, E., Balan, L., & Foltyn, V. N. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06515.x · Cited by 309
Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis
Hardingham, G. E., & Do, K. Q. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.19 · Cited by 304
The NMDA Receptor and Schizophrenia
Balu, D. T. (2016) · Advances in pharmacology · doi:10.1016/bs.apha.2016.01.006 · Cited by 303
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
Lieberman, J. A., Bymaster, F. P., Meltzer, H. Y., Deutch, A. Y., Duncan, G. E., Marx, C. E., Aprille, J. R., Dwyer, D. S., Li, X., Mahadik, S. P., et al. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00107 · Cited by 225
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
Hashimoto, K., Malchow, B., Falkai, P., & Schmitt, A. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0399-y · Cited by 224
Self-citation
Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction
Balu, D. T., Li, Y., Puhl, M. D., Benneyworth, M. A., Basu, A. C., Takagi, S., Bolshakov, V. Y., & Coyle, J. T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304308110 · Cited by 217
The NMDA receptor ‘glycine modulatory site’ in schizophrenia: d-serine, glycine, and beyond
Balu, D. T., & Coyle, J. T. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.12.004 · Cited by 208
Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia
Singh, S. P., & Singh, V. (2011) · CNS Drugs · doi:10.2165/11586650-000000000-00000 · Cited by 194
When Top-Down Meets Bottom-Up: Auditory Training Enhances Verbal Memory in Schizophrenia
Adcock, R. A., Dale, C. L., Fisher, M., Aldebot, S., Genevsky, A., Simpson, G. V., Nagarajan, S. S., & Vinogradov, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp068 · Cited by 197
Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia
Madeira, C., Freitas, M. E., Vargas-Lopes, C., Wolosker, H., & Panizzutti, R. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.02.002 · Cited by 191
Glial D-Serine Gates NMDA Receptors at Excitatory Synapses in Prefrontal Cortex
Fossat, P., Turpin, F. R., Sacchi, S., Dulong, J., Shi, T., Rivet, J., Sweedler, J. V., Pollegioni, L., Millan, M. J., Oliet, S. H. R., et al. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhr130 · Cited by 197
Calcium signalling and psychiatric disease: bipolar disorder and schizophrenia
Berridge, M. J. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1806-z · Cited by 181
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180
d ‐Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia
Louise, V., Walker, M. A., Rawlings, N. B., Benzel, I. M., Kew, J. N. C., Harrison, P. J., & Burnet, P. W. J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05769.x · Cited by 176
The neurobiology of D-amino acid oxidase and its involvement in schizophrenia
Verrall, L., Burnet, P. W. J., Betts, J. F., & Harrison, P. J. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.99 · Cited by 173
Translating Glutamate: From Pathophysiology to Treatment
Javitt, D. C., Schoepp, D., Kalivas, P. W., Volkow, N. D., Zarate, C., Merchant, K., Bear, M. F., Umbricht, D., Hajos, M., Potter, W. Z., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002804 · Cited by 168
NMDA Receptor Regulation by D-serine: New Findings and Perspectives
Wolosker, H. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0038-6 · Cited by 157
Glutamate signaling in the pathophysiology and therapy of schizophrenia
Lin, C., Lane, H., & Tsai, G. E. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.023 · Cited by 154
Brain-specific Phgdh Deletion Reveals a Pivotal Role for l-Serine Biosynthesis in Controlling the Level of d-Serine, an N-methyl-d-aspartate Receptor Co-agonist, in Adult Brain
Yang, J. H., Wada, A., Yoshida, K., Miyoshi, Y., Sayano, T., Esaki, K., Kinoshita, M. O., Tomonaga, S., Azuma, N., Watanabe, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.187443 · Cited by 153
Unconventional NMDA Receptor Signaling
Doré, K., Stein, I. S., Brock, J. A., Castillo, P. E., Zito, K., & Sjöström, P. J. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1825-17.2017 · Cited by 148
Identification of Multiple Serine Racemase (SRR) mRNA Isoforms and Genetic Analyses of SRR and DAO in Schizophrenia and d-Serine Levels
Yamada, K., Ohnishi, T., Hashimoto, K., Ohba, H., Iwayama‐Shigeno, Y., Toyoshima, M., Okuno, A., Takao, H., Toyota, T., Minabe, Y., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.018 · Cited by 147
Self-citation
Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia
Labrie, V., Lipina, T. V., & Roder, J. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1196-6 · Cited by 141
Synthesis and Biological Evaluation of d -Amino Acid Oxidase Inhibitors
Ferraris, D. V., Duvall, B. R., Ko, Y.-S., Thomas, A. G., Rojas, C. J., Majer, P., Hashimoto, K., & Tsukamoto, T. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800200u · Cited by 135
Self-citation
Allosteric modulation of NMDA receptor via elevation of brain glycine and d-serine: The therapeutic potentials for schizophrenia
Yang, C. R., & Svensson, K. A. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.08.004 · Cited by 129
Co-Administration of a D-Amino Acid Oxidase Inhibitor Potentiates the Efficacy of D-Serine in Attenuating Prepulse Inhibition Deficits After Administration of Dizocilpine
Hashimoto, K., Fujita, Y., Horio, M., Kunitachi, S., Iyo, M., Ferraris, D. V., & Tsukamoto, T. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.002 · Cited by 128
Self-citation
D-Serine: Potential Therapeutic Agent and/or Biomarker in Schizophrenia and Depression?
MacKay, M.-A. B., Kravtsenyuk, M., Thomas, R. K., Mitchell, N., Dursun, S. M., & Baker, G. B. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00025 · Cited by 128
Immunocytochemical analysis of D ‐serine distribution in the mammalian brain reveals novel anatomical compartmentalizations in glia and neurons
Williams, S. M., Díaz, C., Macnab, L. T., Sullivan, R., & Pow, D. V. (2005) · Glia · doi:10.1002/glia.20300 · Cited by 126
Human D-Amino Acid Oxidase: Structure, Function, and Regulation
Pollegioni, L., Sacchi, S., & Murtas, G. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00107 · Cited by 127
In Sickness and in Health: Perineuronal Nets and Synaptic Plasticity in Psychiatric Disorders
Pantazopoulos, H., & Berretta, S. (2015) · Neural Plasticity · doi:10.1155/2016/9847696 · Cited by 128
In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties
Adage, T., Trillat, A., Quattropani, A., Perrin, D., Cavarec, L., Shaw, J., Guerassimenko, O., Giachetti, C., Greco, B. M., Chumakov, I. M., et al. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.06.006 · Cited by 119
Contributions of the d-serine pathway to schizophrenia
Labrie, V., Wong, A. H. C., & Roder, J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.030 · Cited by 121
Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry
Hanson, J. E., Yuan, H., Perszyk, R. E., Banke, T. G., Xing, H., Tsai, M., Menniti, F. S., & Traynelis, S. F. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01614-3 · Cited by 121
The involvement of the NMDA receptor d-serine/glycine site in the pathophysiology and treatment of schizophrenia
Labrie, V., & Roder, J. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.08.002 · Cited by 118
Targeting of NMDA receptors in new treatments for schizophrenia
Hashimoto, K. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.934225 · Cited by 117
Self-citation
Brain, blood, cerebrospinal fluid, and serum biomarkers in schizophrenia
Mohammadi, A., Rashidi, E., & Amooeian, V. G. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.04.036 · Cited by 119
Theranostic Biomarkers for Schizophrenia
Perković, M. N., Erjavec, G. N., Štrac, D. Š., Uzun, S., Kozumplik, O., & Pivac, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040733 · Cited by 113
Levels of d-serine in the brain and peripheral organs of serine racemase (Srr) knock-out mice
Horio, M., Kohno, M., Fujita, Y., Ishima, T., Inoue, R., Mori, H., & Hashimoto, K. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.08.017 · Cited by 105
Self-citation
Decreased levels of d-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia
Errico, F., Napolitano, F., Squillace, M., Vitucci, D., Blasi, G., de Bartolomeis, A., Bertolino, A., D’Aniello, A., & Usiello, A. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.06.013 · Cited by 105
Dendritic Spine Elimination: Molecular Mechanisms and Implications
Stein, I. S., & Zito, K. (2018) · The Neuroscientist · doi:10.1177/1073858418769644 · Cited by 110
The NMDA receptor co-agonists, d-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex
Balu, D. T., Basu, A. C., Corradi, J., Cacace, A. M., & Coyle, J. T. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.006 · Cited by 104
d-Amino acid metabolism in mammals: Biosynthesis, degradation and analytical aspects of the metabolic study
Ohide, H., Miyoshi, Y., Maruyama, R., Hamase, K., & Konno, R. (2011) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.06.028 · Cited by 96
Changes in plasma glycine, l-serine, and d-serine levels in patients with schizophrenia as their clinical symptoms improve: Results from the Juntendo University Schizophrenia Projects (JUSP)
Ohnuma, T., Sakai, Y., Maeshima, H., Hatano, T., Hanzawa, R., Abe, S., Kida, S., Shibata, N., Suzuki, T., & Arai, H. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.07.022 · Cited by 93
Effects of low-dose d-serine on recognition and working memory in mice
Bado, P., Madeira, C., Vargas-Lopes, C., Moulin, T. C., Wasilewska‐Sampaio, A. P., Maretti, L., de Oliveira, R. V., Amaral, O. B., & Panizzutti, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2330-4 · Cited by 94
Genetic inactivation of D-amino acid oxidase enhances extinction and reversal learning in micePreprint
Labrie, V., Duffy, S. N., Wang, W., Barger, S. W., Baker, G. B., & Roder, J. (2008) · Learning & Memory · doi:10.1101/lm.1112209 · Cited by 90
Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse
Coyle, J. T., Ruzicka, W. B., & Balu, D. T. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20101481 · Cited by 84
The Therapeutic Potential of D-Amino Acid Oxidase (DAAO) Inhibitors
Smith, S. M., Uslaner, J. M., & Hutson, P. H. (2010) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501004020003 · Cited by 84
The Behavioral and Neurochemical Effects of a Novel d-Amino Acid Oxidase Inhibitor Compound 8 [4 H-Thieno [3,2-b]pyrrole-5-carboxylic Acid] and d-Serine
Smith, S. M., Uslaner, J. M., Yao, L., Mullins, C. M., Surles, N. O., Huszar, S. L., McNaughton, C. H., Pascarella, D. M., Kandebo, M., Hinchliffe, R. M., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.147884 · Cited by 84
Plasma levels of D-serine in Brazilian individuals with schizophrenia
Calcia, M., Madeira, C., Alheira, F. V., da Silva, T. C. S., Tannos, F. M., Vargas-Lopes, C., Goldenstein, N., Brasil, M. A. A., Ferreira, S. T., & Panizzutti, R. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.09.014 · Cited by 83
Low d-serine levels in schizophrenia: A systematic review and meta-analysis
Cho, S., Na, K., Cho, S.-J., & Kang, S. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.10.006 · Cited by 83
Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia
Boks, M. P., Rietkerk, T., van de Beek, M. H., Sommer, I. E., de Koning, T. J., & Kahn, R. S. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.12.003 · Cited by 80
d-Amino Acids and Lactic Acid Bacteria
Kobayashi, J. (2019) · Microorganisms · doi:10.3390/microorganisms7120690 · Cited by 77
Changes in plasma d-serine, l-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment
Yamamori, H., Hashimoto, R., Fujita, Y., Numata, S., Yasuda, Y., Fujimoto, M., Ohi, K., Umeda‐Yano, S., Itô, A., Ohmori, T., et al. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.08.052 · Cited by 75
Self-citation
Preliminary evidence for a link between schizophrenia and NMDA–glycine site receptor ligand metabolic enzymes, d -amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1)
Kapoor, R., Lim, K. S., Cheng, A., Garrick, T. M., & Kapoor, V. (2006) · Brain Research · doi:10.1016/j.brainres.2006.05.082 · Cited by 73
Mutant mice with reduced NMDA-NR1 glycine affinity or lack of d-amino acid oxidase function exhibit altered anxiety-like behaviors
Labrie, V., Clapcote, S. J., & Roder, J. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.09.016 · Cited by 73
Decreased free d-aspartate levels are linked to enhanced d-aspartate oxidase activity in the dorsolateral prefrontal cortex of schizophrenia patients
Nuzzo, T., Sacchi, S., Errico, F., Keller, S., Palumbo, O., Florio, E., Punzo, D., Napolitano, F., Copetti, M., Carella, M., et al. (2017) · Schizophrenia · doi:10.1038/s41537-017-0015-7 · Cited by 72
Current Trends on Surface Acoustic Wave Biosensors
Zida, S. I., Lin, Y., & Khung, Y. L. (2021) · Advanced Materials Technologies · doi:10.1002/admt.202001018 · Cited by 70
d ‐Amino acids in biological systems
Du, S., Wey, M., & Armstrong, D. W. (2023) · Chirality · doi:10.1002/chir.23562 · Cited by 76
Substance use disorders and schizophrenia: A question of shared glutamatergic mechanisms
Coyle, J. T. (2006) · Neurotoxicity Research · doi:10.1007/bf03033359 · Cited by 71
The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes
Drago, A., Crisafulli, C., Sidoti, A., & Serretti, A. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.05.009 · Cited by 71
Behavioral and cognitive effects of the N-methyl-d-aspartate receptor co-agonist d-serine in healthy humans: Initial findings
Levin, R., Dor-Abarbanel, A. E., Edelman, S., Durrant, A. R., Hashimoto, K., Javitt, D. C., & Heresco‐Levy, U. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.12.007 · Cited by 67
Self-citation
Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update
Chaves, C., de Marque, C. R., Trzesniak, C. M. F., de Sousa, J. P. M., Zuardi, A. W., Crippa, J. A. S., Dursun, S. M., & Hallak, J. E. C. (2009) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2009001100002 · Cited by 64
Potential and Challenges for the Clinical Use of d-Serine As a Cognitive Enhancer
Guercio, G. D., & Panizzutti, R. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00014 · Cited by 67
The Role of D-Amino Acids in Alzheimer’s Disease
Piubelli, L., Murtas, G., Rabattoni, V., & Pollegioni, L. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201217 · Cited by 63
The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial
O’Donnell, P., Dong, C., Murthy, V., Asgharnejad, M., Du, X. M., Summerfelt, A. T., Lu, H., Xu, L., Wendland, J. R., Dunayevich, E., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01560-0 · Cited by 60
Free D-aspartate regulates neuronal dendritic morphology, synaptic plasticity, gray matter volume and brain activity in mammals
Errico, F., Nisticò, R., Giorgio, A. D., Squillace, M., Vitucci, D., Galbusera, A., Piccinin, S., Mango, D., Fazio, L., Middei, S., et al. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.59 · Cited by 58
The Role of Biomarkers in Psychiatry
Lozupone, M., Montagna, M. L., D’Urso, F., Daniele, A., Greco, A., Seripa, D., Logroscino, G., Bellomo, A., & Panza, F. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-05542-4_7 · Cited by 64
The Role of Serine Racemase in the Pathophysiology of Brain Disorders
Coyle, J. T., & Balu, D. T. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.10.002 · Cited by 58
Markers of glutamate signaling in cerebrospinal fluid and serum from patients with bipolar disorder and healthy controls
Pålsson, E., Jakobsson, J., Södersten, K., Fujita, Y., Sellgren, C. M., Ekman, C. J., Ågren, H., Hashimoto, K., & Landén, M. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.11.001 · Cited by 55
Self-citation
Molecular Mechanisms of Non-ionotropic NMDA Receptor Signaling in Dendritic Spine Shrinkage
Stein, I. S., Park, D. K., Jahncke, J. N., Flores, J. C., & Zito, K. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.0046-20.2020 · Cited by 57
Multiple faces of protein interacting with C kinase 1 (PICK1): Structure, function, and diseases.
Li, Y., Zhang, N., Wang, Y.-N., Shen, Y., & Wang, Y. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.03.001 · Cited by 54
Biosensors for D-Amino Acids: Detection Methods and Applications
Rosini, E., D’Antona, P., & Pollegioni, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134574 · Cited by 53
A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice
Errico, F., D’Argenio, V., Sforazzini, F., Iasevoli, F., Squillace, M., Guerri, G., Napolitano, F., Angrisano, T., Maio, A. D., Keller, S., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.2 · Cited by 53
Potential pathophysiological role of d-amino acid oxidase in schizophrenia: immunohistochemical and in situ hybridization study of the expression in human and rat brain
Ono, K., Shishido, Y., Park, H. K., Kawazoe, T., Iwana, S., Chung, S. P., El-Magd, R. M. A., Yorita, K., Okano, M., Watanabe, T., et al. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0289-7 · Cited by 53
Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment
Hung, C.-C., Lin, C., & Lane, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189718 · Cited by 52
Association between increased serum d-serine and cognitive gains induced by intensive cognitive training in schizophrenia
Panizzutti, R., Fisher, M., Garrett, C. T., Man, W. H., Sena, W., Madeira, C., & Vinogradov, S. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.04.011 · Cited by 52
Cerebrospinal fluid d-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients
Fuchs, S. A., de Barse, M. M. J., Scheepers, F. E., Cahn, W., DORLAND, L., der Velden, M. G. M. D. S., Klomp, L. W. J., Berger, R., Kahn, R. S., & de Koning, T. J. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.12.002 · Cited by 52
Glycine and d-serine, but not d-cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801
Kanahara, N., Shimizu, E., Ohgake, S., Fujita, Y., Kohno, M., Hashimoto, T., Matsuzawa, D., Shirayama, Y., Hashimoto, K., & Iyo, M. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1151-6 · Cited by 51
Self-citation
Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine
Matsuura, A., Fujita, Y., Iyo, M., & Hashimoto, K. (2015) · Acta Neuropsychiatrica · doi:10.1017/neu.2015.1 · Cited by 49
Self-citation
Novel high-throughput and widely-targeted liquid chromatography–time of flight mass spectrometry method for d-amino acids in foods
Konya, Y., Taniguchi, M., & Fukusaki, E. (2016) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2016.07.009 · Cited by 49
Serine racemase protein expression in cortex and hippocampus in schizophrenia
Steffek, A. E., Haroutunian, V. H., & Meador‐Woodruff, J. H. (2006) · Neuroreport · doi:10.1097/01.wnr.0000230512.01339.72 · Cited by 49
Evidence for the association of the DAOA (G72) gene with schizophrenia and bipolar disorder but not for the association of the DAO gene with schizophrenia
Bass, N. J., Datta, S. R., McQuillin, A., Puri, V., Choudhury, K., Thirumalai, S., Lawrence, J., Quested, D. J., Pimm, J., Curtis, D., et al. (2009) · Behavioral and Brain Functions · doi:10.1186/1744-9081-5-28 · Cited by 48
D-Serine and Serine Racemase Are Associated with PSD-95 and Glutamatergic Synapse Stability
Lin, H., Jacobi, A. A., Anderson, S. A., & Lynch, D. R. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00034 · Cited by 47
Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?
Vasić, N., Connemann, B. J., Wolf, R. C., Tumani, H., & Brettschneider, J. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0280-9 · Cited by 46
Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia
Burnet, P. W. J., Hutchinson, L. J., VONHESLING, M., Gilbert, E. M., Brandon, N. J., Rutter, A. R., Hutson, P. H., & Harrison, P. J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.02.009 · Cited by 45
4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d -Amino Acid Oxidase Inhibitors
Hondo, T., Warizaya, M., Niimi, T., Namatame, I., Yamaguchi, T., Nakanishi, K., Hamajima, T., Harada, K., Sakashita, H., Matsumoto, Y., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400095b · Cited by 44
Identification of Novel d -Amino Acid Oxidase Inhibitors by in Silico Screening and Their Functional Characterization in Vitro
Katane, M., Osaka, N., Matsuda, S., Maeda, K., Kawata, T., Saitoh, Y., Sekine, M., Furuchi, T., Doi, I., Hirono, S., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017865 · Cited by 44
Two Mass-Spectrometric Techniques for Quantifying Serine Enantiomers and Glycine in Cerebrospinal Fluid: Potential Confounders and Age-Dependent Ranges
Fuchs, S. A., der Velden, M. G. M. D. S., de Barse, M. M. J., Roeleveld, M. W., Hendriks, M. W. B., DORLAND, L., Klomp, L. W. J., Berger, R., & de Koning, T. J. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.100412 · Cited by 44
D-Serine in Neurobiology: CNS Neurotransmission and Neuromodulation
Bardaweel, S. K., Alzweiri, M. H., & Ishaqat, A. (2014) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s031716710001653x · Cited by 44
Serine hydroxymethyltransferase 1 and 2: gene sequence variation and functional genomic characterization
Hebbring, S. J., Chai, Y., Ji, Y., Abo, R., Jenkins, G. D., Fridley, B. L., Zhang, J., Eckloff, B. W., Wieben, E. D., & Weinshilboum, R. M. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07646.x · Cited by 43
Arketamine for cognitive impairment in psychiatric disorders
Hashimoto, K. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01570-5 · Cited by 42
Self-citation

Authors: Hashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindström, L. H., & Iyo, M.
Affiliations: Chiba University (JP)
Karolinska Institutet (SE)
Linköping University Hospital (SE)
Uppsala University (SE)
Corresponding author: Hashimoto, Kenji
ORCID: Hashimoto, Kenji
Engberg, Göran
Shimizu, Eiji
Iyo, Masaomi
Venue: Progress in Neuro-Psychopharmacology and Biological Psychiatry
Publisher: Elsevier BV
Published: 2005-06
Volume: 29
Issue: 5
Pages: 767-769
ISSN: 0278-5846 (ISSN-L)
DOI: 10.1016/j.pnpbp.2005.04.023
OpenAlex: W2078450450
Cited by: 267
References: 13
Citations by year: 2026: 8 · 2025: 10 · 2024: 11 · 2023: 10 · 2022: 6 · 2021: 7 · 2020: 12 · 2019: 18 · 2018: 15 · 2017: 12 · 2016: 16 · 2015: 13 · 2014: 12 · 2013: 14 · 2012: 14
FWCI: 8.86
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: D-serine, L-serine, cerebrospinal fluid, schizophrenia, first-episode schizophrenia, drug-naive patients, NMDA receptor, serine metabolism
MeSH terms: Adolescent, Adult, Chromatography, High Pressure Liquid, Humans, Male, Schizophrenia, Serine, Stereoisomerism, Receptors, N-Methyl-D-Aspartate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks